4.8 Article

Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico

期刊

CELL
卷 169, 期 4, 页码 597-609

出版社

CELL PRESS
DOI: 10.1016/j.cell.2017.04.024

关键词

-

资金

  1. NIH [U19AI111825, UL1TR001866, R01AI037526, UM1AI100663, R01AI121207, R01TW009504, R25TW009338, U01AI088752, R01AI124690, U19AI057229]
  2. Molecular Observatory at Caltech - Gordon and Betty Moore Foundation
  3. Robertson Therapeutic Development Fund
  4. Pew Latin American Fellows Program in the Biomedical Sciences
  5. Studienstiftung des deutschen Volkes
  6. Austrian Marshall Plan Foundation
  7. Red INMUNOCANEI-Conacyt

向作者/读者索取更多资源

Antibodies to Zika virus (ZIKV) can be protective. To examine the antibody response in individuals who develop high titers of anti-ZIKV antibodies, we screened cohorts in Brazil and Mexico for ZIKV envelope domain III (ZEDIII) binding and neutralization. We find that serologic reactivity to dengue 1 virus (DENV1) EDIII before ZIKV exposure is associated with increased ZIKV neutralizing titers after exposure. Antibody cloning shows that donors with high ZIKV neutralizing antibody titers have expanded clones of memory B cells that express the same immunoglobulin VH3-23/VK1-5 genes. These recurring antibodies cross-react with DENV1, but not other flaviviruses, neutralize both DENV1 and ZIKV, and protect mice against ZIKV challenge. Structural analyses reveal the mechanism of recognition of the ZEDIII lateral ridge by VH3-23/VK1-5 antibodies. Serologic testing shows that antibodies to this region correlate with serumneutralizing activity to ZIKV. Thus, high neutralizing responses to ZIKV are associated with pre-existing reactivity to DENV1 in humans.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据